Xenofon Baralikos (Ruhr-University, Bochum, Germany) discusses with touchIMMUNOLOGY the findings from the post hoc analysis of 4 RCT trials investigating the time frames of clinical response in patients with axial spondyloarthritis receiving etanercept.
His abstract ‘Temporal Achievement of Clinical Response and Inactive Disease Status in Patients with Axial Spondyloarthritis Treated with Etanercept’ (ABSTRACT NUMBER: 0897) was presented at ACR Convergence 2020, 5-9 November.
Questions
- Where does etanercept sit in the treatment paradigm for patients with axial spondyloarthritis? (0:15)
- What were the aims of your recent analysis of data from studies evaluating the safety and efficacy of etanercept in the treatment of patients with axial spondyloarthritis? (1:14)
- What were the findings of the study and what factors determined an early response? (2:23)
- What are the implications of these findings for clinical practice? (4:19)
Disclosures: Xenofon Baralikos has nothing to disclose in relation to this video interview.
Support: Â Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
